A Dual-acceptor Time-resolved Föster Resonance Energy Transfer Assay for Simultaneous Determination of Thyroid Hormone Regulation of Corepressor and Coactivator Binding to the Thyroid Hormone Receptor: Mimicking the Cellular Context of Thyroid...

Overview

Journal Anal Biochem

Publisher Elsevier

Specialty Biochemistry

Date 2008 Dec 30

PMID 19111515

Citations 10

Authors

M Jeyakumar

John A Katzenellenbogen

Affiliations

Soon will be listed here.

Abstract

Previously, we reported the development of two in vitro time-resolved Föster resonance energy transfer (tr-FRET)-based assays for evaluating the potency and efficacy of different ligands of thyroid hormone receptor (TR) for regulating the recruitment of coregulators. We could measure independently, in separate assays, both the recruitment of SRC3 (steroid receptor coactivator 3, a transcriptional coactivator) and the dissociation of NCoR (nuclear receptor corepressor, a transcriptional corepressor) from a TR*retinoid X receptor (RXR) heterodimer bound to a DR+4 thyroid hormone response element (TRE). Here, by using the distinct emission peaks of Tb(3+), the donor fluorophore used to label the TRE-bound TR*RXR heterodimers, and selecting two distinct acceptor fluorophores, fluorescein and cyanine 5, to label of NCoR and SRC3, respectively, we have integrated our previous two assay formats into a single assay. Thus, we can measure the potency of TR ligands simultaneously for NCoR dissociation and SRC3 recruitment activities in a system that mimics many features of the cellular context of TR action. The performance of this dual assay was tested with a known, highly potent physiological TR ligand, triiodothyronine (T(3)), and with a synthetic TR antagonist, NH-3. Measured potencies and efficacies of these two TR ligands from this dual assay are highly comparable to those obtained from the two independent assays. Thus, this dual-acceptor tr-FRET assay further simplifies the measurement of ligand-modulated TR-coregulator interactions and should improve the overall efficiency of the screening process of TR drug discovery programs.

Citing Articles

A multiplexed time-resolved fluorescence resonance energy transfer ultrahigh-throughput screening assay for targeting the SMAD4-SMAD3-DNA complex.

Ouyang W, Li Q, Niu Q, Qui M, Fu H, Du Y J Mol Cell Biol. 2023; 15(11).

PMID: 37968137 PMC: 11063955. DOI: 10.1093/jmcb/mjad068.

Rational design of a sensitivity-enhanced tracer for discovering efficient APC-Asef inhibitors.

Zhong J, Guo Y, Lu S, Song K, Wang Y, Feng L Nat Commun. 2022; 13(1):4961.

PMID: 36002443 PMC: 9402538. DOI: 10.1038/s41467-022-32612-6.

Using TR-FRET to Investigate Protein-Protein Interactions: A Case Study of PXR-Coregulator Interaction.

Lin W, Chen T Adv Protein Chem Struct Biol. 2018; 110:31-63.

PMID: 29412999 PMC: 5815392. DOI: 10.1016/bs.apcsb.2017.06.001.

Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues.

Madak-Erdogan Z, Kim S, Gong P, Zhao Y, Zhang H, Chambliss K Sci Signal. 2016; 9(429):ra53.

PMID: 27221711 PMC: 4896643. DOI: 10.1126/scisignal.aad8170.

Multicolored, Tb³⁺-Based Antibody-Free Detection of Multiple Tyrosine Kinase Activities.

Lipchik A, Perez M, Cui W, Parker L Anal Chem. 2015; 87(15):7555-8.

PMID: 26207839 PMC: 4707937. DOI: 10.1021/acs.analchem.5b02233.

References

Nguyen N, Apriletti J, Cunha Lima S, Webb P, Baxter J, Scanlan T . Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem. 2002; 45(15):3310-20. DOI: 10.1021/jm0201013. View

Liu J, Knappenberger K, Kack H, Andersson G, Nilsson E, Dartsch C . A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment. Mol Endocrinol. 2003; 17(3):346-55. DOI: 10.1210/me.2002-0331. View

Lazar M . Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev. 1993; 14(2):184-93. DOI: 10.1210/edrv-14-2-184. View

Clamme J, Deniz A . Three-color single-molecule fluorescence resonance energy transfer. Chemphyschem. 2005; 6(1):74-7. DOI: 10.1002/cphc.200400261. View

Ozers M, Marks B, Gowda K, Kupcho K, Ervin K, De Rosier T . The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry. 2007; 46(3):683-95. DOI: 10.1021/bi061321b. View

Jeyakumar M, Liu X, Erdjument-Bromage H, Tempst P, Bagchi M . Phosphorylation of thyroid hormone receptor-associated nuclear receptor corepressor holocomplex by the DNA-dependent protein kinase enhances its histone deacetylase activity. J Biol Chem. 2007; 282(13):9312-9322. DOI: 10.1074/jbc.M609009200. View

Privalsky M . The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol. 2004; 66:315-60. DOI: 10.1146/annurev.physiol.66.032802.155556. View

Yen P, Ando S, Feng X, Liu Y, Maruvada P, Xia X . Thyroid hormone action at the cellular, genomic and target gene levels. Mol Cell Endocrinol. 2006; 246(1-2):121-7. DOI: 10.1016/j.mce.2005.11.030. View

Bramlett K, Wu Y, Burris T . Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol Endocrinol. 2001; 15(6):909-22. DOI: 10.1210/mend.15.6.0649. View

10.

Zhou G, Cummings R, Li Y, Mitra S, Wilkinson H, Elbrecht A . Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Mol Endocrinol. 1998; 12(10):1594-604. DOI: 10.1210/mend.12.10.0176. View

11.

Kim S, Tamrazi A, Carlson K, Katzenellenbogen J . A proteomic microarray approach for exploring ligand-initiated nuclear hormone receptor pharmacology, receptor selectivity, and heterodimer functionality. Mol Cell Proteomics. 2004; 4(3):267-77. DOI: 10.1074/mcp.M400192-MCP200. View

12.

Hohng S, Joo C, Ha T . Single-molecule three-color FRET. Biophys J. 2004; 87(2):1328-37. PMC: 1304471. DOI: 10.1529/biophysj.104.043935. View

13.

Margeat E, Poujol N, Boulahtouf A, Chen Y, Muller J, Gratton E . The human estrogen receptor alpha dimer binds a single SRC-1 coactivator molecule with an affinity dictated by agonist structure. J Mol Biol. 2001; 306(3):433-42. DOI: 10.1006/jmbi.2000.4418. View

14.

Grover G, Mellstrom K, Malm J . Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes. Curr Vasc Pharmacol. 2007; 5(2):141-54. DOI: 10.2174/157016107780368271. View

15.

Stafslien D, Vedvik K, De Rosier T, Ozers M . Analysis of ligand-dependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay. Mol Cell Endocrinol. 2006; 264(1-2):82-9. DOI: 10.1016/j.mce.2006.10.016. View

16.

Kupcho K, Stafslien D, DeRosier T, Hallis T, Ozers M, Vogel K . Simultaneous monitoring of discrete binding events using dual-acceptor terbium-based LRET. J Am Chem Soc. 2007; 129(44):13372-3. DOI: 10.1021/ja074791h. View

17.

Koehler K, Gordon S, Brandt P, Carlsson B, Backsbro-Saeidi A, Apelqvist T . Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor. J Med Chem. 2006; 49(23):6635-7. DOI: 10.1021/jm060521i. View

18.

Tamrazi A, Katzenellenbogen J . Site-specific fluorescent labeling of estrogen receptors and structure-activity relationships of ligands in terms of receptor dimer stability. Methods Enzymol. 2003; 364:37-53. DOI: 10.1016/s0076-6879(03)64003-6. View

19.

Baxter J, Webb P, Grover G, Scanlan T . Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab. 2004; 15(4):154-7. DOI: 10.1016/j.tem.2004.03.008. View

20.

Liu J, Lu Y . FRET study of a trifluorophore-labeled DNAzyme. J Am Chem Soc. 2002; 124(51):15208-16. DOI: 10.1021/ja027647z. View